Monoclonal antibody · Antagonist of insulin-like growth factor-1 receptor (IGF1R) · developed by Viridian Therapeutics
Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor (IGF-1R) and blocks ligand-induced receptor autophosphorylation, inhibiting IGF-1R signaling. It is studied in thyroid eye disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 29, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07832136 | Phase 4 | Thyroid Eye Disease | Not yet recruiting | VRDN |
| NCT06179875 | Phase 3 | Thyroid Eye Disease | Completed | VRDN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Thyroid Eye Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the VRDN page.
See VRDN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VRDN catalysts and pipeline →